Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Portfolio Pulse from Vandana Singh
Quest Diagnostics (NYSE: DGX) reported Q2 adjusted EPS of $2.35, slightly beating the consensus of $2.34. Sales increased by 2.5% year-over-year to $2.39 billion, in line with expectations. The company revised its fiscal year 2024 revenue guidance upwards and forecasts adjusted EPS of $8.80-$9.00. William Blair rates the stock as Outperform, noting stable performance and potential for modest growth.
July 23, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics reported Q2 adjusted EPS of $2.35, slightly beating the consensus. Sales increased by 2.5% year-over-year to $2.39 billion. The company revised its fiscal year 2024 revenue guidance upwards and forecasts adjusted EPS of $8.80-$9.00. William Blair rates the stock as Outperform, noting stable performance and potential for modest growth.
Quest Diagnostics' Q2 performance slightly exceeded expectations, and the company revised its fiscal year 2024 guidance upwards. William Blair's Outperform rating and the positive outlook for modest growth suggest a likely short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100